Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Long-Term Investments (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Long-Term Investments for 12 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments rose 385.51% to $11.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.1 million through Dec 2025, up 385.51% year-over-year, with the annual reading at $11.1 million for FY2025, 385.51% up from the prior year.
  • Long-Term Investments for Q4 2025 was $11.1 million at Theravance Biopharma, up from $3.0 million in the prior quarter.
  • The five-year high for Long-Term Investments was $148.2 million in Q2 2022, with the low at $2.3 million in Q4 2024.
  • Average Long-Term Investments over 5 years is $37.5 million, with a median of $19.1 million recorded in 2021.
  • The sharpest move saw Long-Term Investments skyrocketed 429.7% in 2021, then plummeted 80.05% in 2023.
  • Over 5 years, Long-Term Investments stood at $67.5 million in 2021, then soared by 119.51% to $148.2 million in 2022, then plummeted by 87.33% to $18.8 million in 2023, then crashed by 87.79% to $2.3 million in 2024, then surged by 385.51% to $11.1 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $11.1 million, $3.0 million, and $2.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.